DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.
作者信息
Henry Brandy
出版信息
J Health Biomed Law. 2018 Sep;14:265-283.
Abstract
摘要
相似文献
1
DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.
J Health Biomed Law. 2018 Sep;14:265-283.
2
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.
3
The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition.
Liver Int. 2022 Jul;42(7):1503-1516. doi: 10.1111/liv.15245. Epub 2022 Mar 26.
4
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.
J Public Health Manag Pract. 2019 May/Jun;25(3):245-252. doi: 10.1097/PHH.0000000000000829.
5
Pharma Pricing & Market Access Europe 2016--Health Network Communications' Tenth Annual Conference (February 23-25, 2016--London, UK).
Drugs Today (Barc). 2016 Mar;52(3):203-6. doi: 10.1358/dot.2016.52.3.2480580.
6
Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.
Pharmaceut Med. 2022 Oct;36(5):265-274. doi: 10.1007/s40290-022-00443-x. Epub 2022 Aug 22.
7
The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Health Econ. 2019 Aug;28(8):1035-1051. doi: 10.1002/hec.3903.
8
Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform.
J Mark Access Health Policy. 2016 Mar 15;4. doi: 10.3402/jmahp.v4.30458. eCollection 2016.
9
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
10
Market access and value-based pricing of digital health applications in Germany.
Cost Eff Resour Alloc. 2022 Jun 13;20(1):25. doi: 10.1186/s12962-022-00359-y.
引用本文的文献
1
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.
PLOS Glob Public Health. 2025 Jan 16;5(1):e0003284. doi: 10.1371/journal.pgph.0003284. eCollection 2025.
2
340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
JAMA Health Forum. 2024 Oct 4;5(10):e243360. doi: 10.1001/jamahealthforum.2024.3360.
3
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.
Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.
4
Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease.
Eur J Cancer Prev. 2024 Nov 1;33(6):512-524. doi: 10.1097/CEJ.0000000000000885. Epub 2024 Mar 22.
5
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.
Curr Oncol. 2023 Jan 18;30(2):1363-1380. doi: 10.3390/curroncol30020105.
6
Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast].
Int J Gen Med. 2022 Oct 26;15:7879-7884. doi: 10.2147/IJGM.S390689. eCollection 2022.
7
Morin encapsulated chitosan nanoparticles (MCNPs) ameliorate arsenic induced liver damage through improvement of the antioxidant system and prevention of apoptosis and inflammation in mice.
Nanoscale Adv. 2022 May 17;4(13):2857-2872. doi: 10.1039/d2na00167e. eCollection 2022 Jun 28.
8
Factors Underlying Racial Disparity in Utilization of Hepatitis C-Viremic Kidneys in the United States.
J Racial Ethn Health Disparities. 2023 Oct;10(5):2185-2194. doi: 10.1007/s40615-022-01398-0. Epub 2022 Aug 23.
9
Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.
Value Health. 2022 Jul;25(7):1141-1147. doi: 10.1016/j.jval.2021.11.1375. Epub 2022 Feb 24.
10
Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
PLoS One. 2021 Aug 27;16(8):e0256816. doi: 10.1371/journal.pone.0256816. eCollection 2021.
本文引用的文献
1
Hepatitis C treatment: Back to the warehouse.
Clin Liver Dis (Hoboken). 2015 Aug 24;6(2):27-29. doi: 10.1002/cld.490. eCollection 2015 Aug.
2
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
JAMA. 2016;316(8):858-71. doi: 10.1001/jama.2016.11237.
3
New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison.
Cost Eff Resour Alloc. 2015 Oct 6;13:17. doi: 10.1186/s12962-015-0043-y. eCollection 2015.
4
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
PLoS One. 2015 Aug 27;10(8):e0135645. doi: 10.1371/journal.pone.0135645. eCollection 2015.
5
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
Clin Infect Dis. 2015 Dec 15;61(12):1825-30. doi: 10.1093/cid/civ677. Epub 2015 Aug 12.
6
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
BMC Gastroenterol. 2015 Aug 5;15:98. doi: 10.1186/s12876-015-0320-4.
7
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Ann Intern Med. 2015 Aug 4;163(3):226-8. doi: 10.7326/M15-0320.
8
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.
Ann Intern Med. 2015 Aug 4;163(3):215-23. doi: 10.7326/M15-0406.
9
National trends in prescription drug expenditures and projections for 2015.
Am J Health Syst Pharm. 2015 May 1;72(9):717-36. doi: 10.2146/ajhp140849.
10
Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
Clin Ther. 2015 May 1;37(5):1092-112. doi: 10.1016/j.clinthera.2015.02.009. Epub 2015 Apr 4.
Zotero 插件